Medicines can improve your health and biotech penny stocks can improve your wealth.
Since the start of 2021, biotech penny stocks have performed well in the stock market, benefiting so many investors. As these stocks move fast, investors can benefit more from their fluctuations in a short time.
Choosing healthcare or biotech stocks depends on how good are the chances of their rise. And everything happens for a reason. You just need to find out the reason. Lately, the Covid pandemic created a strong demand for new biotech solutions, sicking for the best cure for it.
As per experts penny stock traders, including Tim Sykes 22-year-old a self-made millionaire, these are the best biotech penny stocks to watch this year, along with the explanation to why:
#1 MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD)
MyMD Pharmaceuticals, Inc. is a pharmaceutical company that focuses on developing drug products to cure autoimmune diseases, age-related diseases, and other anxiety and sleep disorders.
The company is working on developing a small molecule for the treatment of various autoimmune diseases. So as an investor, you cannot ignore this point as the company’s stocks have high chances to raise whenever that molecule is ready. And according to sources, it will be this year itself.
Thus, this stock is worth adding to the watchlist. Moreover, it’s important to consider the past performance of these stocks. In that context, the company made an announcement on August 10, that they are preparing to commence the trial of their oral COVID vaccine.”
Within 24 hours of this news, the stocks of this company experienced a great spike, which benefited many day traders. Thus, these stocks have performed well in the past and have great chances to perform in the future too – so you should add them to your portfolio.
#2 Therapeutic Solutions International, Inc. (OTCPK: TSOI)
Therapeutic Solutions International, Inc. is in the business of developing therapies for various diseases. In addition to therapies, they also develop treatments for ageing, inflammation, and sleep apnea.
- On August 5, the company’s JadiCell universal donor stem cell – which was made to treat coronavirus-associated lung diseases – received clearance from the FDA for phase three pivotal trials.
- Also, on August 9, it was announced by the company that they have officially completed all the FDA-required preclinical experiments.
With this, the company has high hopes to receive clearance from FDI for the phase one and phase two trials for chronic traumatic encephalopathy treatments.
After the news, TSOI stocks experienced a good rise. And since the FDI approval is still pending though company chances to get it is high, the opportunities for investors to earn profit from these stocks are still there.
The news related to the approval might come in a few months, so why don’t you add the stock to your watchlist and trade when the right time comes.
#3 Ocugen, Inc. (NASDAQ: OCGN)
Ocugen, Inc. develops treatments for vision loss and a wide range of eye diseases.
- Since the company released a business update and second-quarter earnings, their stocks are performing really well.
- According to the CEO, Shankar Musunuri, “In June, the company signed an amended agreement with The Bharat Biotech company which increased the company’s ability to manufacture, develop and commercialize their Covaxin in Canada.”
The company is planning to share more updates related to this agreement shortly. These updates might be a game-changer for these stocks. They might experience an increase this year.
Some other biotech penny stocks you may add to your watchlist:
#4 Phio Pharmaceuticals Corp. (NASDAQ: PHIO)
#5 IMV Inc. (NASDAQ: IMV)
#6 Outlook Therapeutics, Inc.
With these stocks on your list, there are high chances that you can earn well in the near future. Just keep yourself updated with all the news that might affect these stocks to avoid investing at the wrong time.
This is a Contributor Post. Opinions expressed here are opinions of the Contributor. Influencive does not endorse or review brands mentioned; does not and cannot investigate relationships with brands, products, and people mentioned and is up to the Contributor to disclose. Contributors, amongst other accounts and articles may be professional fee-based.